SRRA: 1.39
52wk Range 1.10 - 2.25
Yesterday very high volume
Volume 1.472.608
Avg. Volume 214,284
Cash and cash equivalents totaled $125.0 million as of March 31, 2017. The company believes that its existing cash and cash equivalents will be sufficient to fund current operating plans through approximately mid-2019. At March 31, 2017, there were 52,268,443 shares of common stock issued and outstanding
= 125 million cash: 52.268.443 shares = $2.393/share.
* Sierra oncology inc says sra737 has been well-tolerated to
date
* Sierra oncology inc - sra737 development program remains
on track
Wall Street is only getting more bullish on the stock, with 2 of analysts who cover SRRA having a buy-equivalent rating. Analysts have placed a $3.17 price target on Sierra Oncology, Inc., suggesting a 143.85% gain from recent close. It’s currently trading about -42.22% below its 52-week high.
high activity on twitter:
$SRRA Sierra Oncology is on the move. Target: 2.50
$SRRA was recently introduced by Dr.KSS at his month cc w/ his readers. Congrats to all longs!
$SRRA very beating down with over 2.30 cash
$SRRA has Cash per sh 2.40$ Just getting started at 1.31
$SRRA volume increase, breaking out of descending triangle
$SRRA biotech trading at less than half cash on balance sheet running today.
$SRRA trading at 50% discount to cash.
$SRRA broke ma 50 and now heading ma 200 around 1.45s
$SRRA with 2+ cash per share still ranging near lows
$SRRA brokers say Buy
Watching $SRRA over 1.34 for a run to $1.5
$SRRA expect a spike to $1.60 soon
$SRRA SURGING TO $1.50......AFTER THAT, A CRAZY BREAKOUT TO $3 .... UNSTOPPABLE $$$$$$$$
$SRRA my brokers said strong buy
$SRRA nice move, starting to go para here huge volume, still way undervalued.
$SRRA finished the day with a hammer candle and a big spike in volume…very very bullish signs. Don’t be surprised this is in the $2s soon.
$SRRA 1.35 on the verge of breakout imo
$SRRA near its big breakout pt....IMO, 1.42 break is a big one for this little stock
Several hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Management LLC bought a position in shares of Sierra Oncology valued at $12,412,000. Perceptive Advisors LLC bought a position in shares of Sierra Oncology valued at $5,667,000. Sabby Management LLC bought a position in shares of Sierra valued at $2,672,000. PNC Financial Services Group Inc. bought a position in shares of Sierra Oncology valued at $1,142,000. Institutional investors and hedge funds own 60.29% of the company’s stock.
5% Stockholders:
Frazier Healthcare VI, L.P. 8,112,121 15.52 %
Affiliates of Deerfield Mgmt, L.P. 4,972,319 9.51 %
OrbiMed Private Investments V, L.P. 3,703,704 7.09 %
Perceptive Advisors, LLC 3,703,704 7.09 %
Directors and Named Executive Officers: 3,121,545 5.72 %
Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
